This blend combines three complementary peptides with distinct mechanisms: AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 177–191) that retains the lipolytic and anti-lipogenic properties of GH without stimulating IGF-1 or affecting glucose metabolism[1][7]. CJC-1295 is a long-acting GHRH analog that produces sustained elevations in growth hormone and IGF-1 levels[2], supporting anabolic processes and fat metabolism. Ipamorelin is a selective ghrelin mimetic that stimulates pulsatile GH secretion without significantly increasing ACTH or cortisol[3], offering a cleaner GH release profile. Together, these peptides work synergistically to enhance endogenous GH pulsatility and promote favorable changes in body composition similar to exogenous GH therapy[4][5].
